Switching from calcineurin inhibitors to sirolimus had an antitumoral effect among kidney-transplant recipients with previous squamous-cell carcinoma. These observations may have implications concerning immunosuppressive treatment of patients with cutaneous squamous-cell carcinomas. (Funded by Hospices Civils de Lyon and others; TUMORAPA ClinicalTrials.gov number, NCT00133887.).
Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., Broeders, N., del Marmol, V., Chatelet, V., Dompmartin, A., Kessler, M., Serra, A. L., Hofbauer, G. F. L., Pouteil-Noble, C., Campistol, J. M., Kanitakis, J., Roux, A. S., Decullier, E., & Dantal, J. (2012). Sirolimus and secondary skin-cancer prevention in kidney transplantation. The New England journal of medicine, 367(4), 329-339. https://doi.org/10.1056/NEJMoa1204166 (Original work published 2012)